



MEETING AGENDA


Pharmacy and Therapeutics Committee

Virtual Meeting

May 19, 2026 - 11:00AM – 5:00PM

Registration: <https://events.teams.microsoft.com/event/670e5ea2-4e1f-414b-8434-714a4032bb15@eacd16bf-dc0e-44db-8e3f-be370c71feca>

TIME	TOPIC/PRESENTER
11:00 PM	Welcome & Introductions: Suzanne Berman, RPH, AHCCCS Pharmacy Director
11:10 PM	SMART Therapy: Dr. Christina Kwong & Dr. Roy Jedeikin
11:30 PM	Minutes Review & Vote - P&T January 13, 2026: Suzanne Berman, RPH
11:35 PM	<p>Supplemental Rebate Drug Class Review: Clinical review by Hind Douiki, PharmD, Prime Therapeutics</p> <ol style="list-style-type: none"> 1. Antibiotics, Inhaled <ol style="list-style-type: none"> a. Public Testimony: None 2. Antimigraine Agents, Other <ol style="list-style-type: none"> a. Public Testimony: None 3. Antipsychotics, Atypical Long-Acting Injectable <ol style="list-style-type: none"> a. Public Testimony: <ol style="list-style-type: none"> i. Stefan Luft – Oral ii. Kristina Sabetta – Oral 4. Antipsychotics, Oral Atypical (2nd Gen Only) <ol style="list-style-type: none"> a. Public Testimony: <ol style="list-style-type: none"> i. Asha-Lee Cadogan – Oral ii. Melanie Oglesby – Oral iii. Garrick Wong – Oral iv. David Delawder – Written v. Miguel Tosado – Written 5. Colony Stimulating Factors <ol style="list-style-type: none"> a. Public Testimony: None 6. COPD Agents <ol style="list-style-type: none"> a. Public Testimony: None 7. Cytokine and CAM Antagonists <ol style="list-style-type: none"> a. Public Testimony: <ol style="list-style-type: none"> i. Melissa Sommers – Oral 8. GI Motility, Chronic <ol style="list-style-type: none"> a. Public Testimony: None 9. Glucagon Agents <ol style="list-style-type: none"> a. Public Testimony: None 10. Growth Hormone



MEETING AGENDA

	<ul style="list-style-type: none"> a. Public Testimony: <ul style="list-style-type: none"> i. Kaysen Bala – Oral ii. Sejal Patel Upadhyaya – Oral iii. Amy Eby – Written <p>11. Hepatitis C Agents</p> <ul style="list-style-type: none"> a. Public Testimony: None <p>12. Hypoglycemics, Incretin Mimetics/Enhancers</p> <ul style="list-style-type: none"> a. Public Testimony: None <p>13. Immunologics (Immunomodulators, Atopic Dermatitis and Immunomodulators, Asthma)</p> <ul style="list-style-type: none"> a. Public Testimony: <ul style="list-style-type: none"> i. Sam Brantman – Oral ii. Matt John – Oral iii. Carla McSpadden – Oral iv. Valerie Ng – Oral v. Jeffery Baldwin – Written vi. Sierra Wolter – Written <p>14. Movement Disorders</p> <ul style="list-style-type: none"> a. Public Testimony: None <p>15. Multiple Sclerosis Agents</p> <ul style="list-style-type: none"> a. Public Testimony: <ul style="list-style-type: none"> i. Payal Tejani – Oral <p>16. Opioid Dependence Treatments</p> <ul style="list-style-type: none"> a. Public Testimony: <ul style="list-style-type: none"> i. John Landis – Oral ii. Rupa Shah – Oral <p>17. Pancreatic Enzymes</p> <ul style="list-style-type: none"> a. Public Testimony: None <p>18. Uterine Disorder Treatments</p> <ul style="list-style-type: none"> a. Public Testimony: None
2:30 PM	<p>New Drug Reviews: Hind Douiki, PharmD</p> <ul style="list-style-type: none"> 1. Lynkuet 2. Redemplo 3. Voyxact 4. Cardamyst 5. Myqorzo
3:00 PM	Break - 15 Minutes
3:15 PM	Executive Session: Nina Bandali, PharmD, Prime Therapeutics
4:15 PM	Public Therapeutic Class Votes: Hind Douiki
4:45 PM	<p>Meeting Adjournment 2026 Meeting Dates: October 7</p>